Indinavir, Zidovudine, Lamivudine: 3-Year Follow-up
Authors: Mark S. Dworkin, Pei-Chun T. Wan
Journal: Annals of Internal Medicine (2001)

Letters16 January 2001Indinavir, Zidovudine, Lamivudine: 3-Year Follow-upMark S. Dworkin, MD, MPHTM and Pei-Chun T. Wan, MSMark S. Dworkin, MD, MPHTMCenters for Disease Control and Prevention; Atlanta, GA 30333 (Dworkin, Wan)Search for more papers by this author and Pei-Chun T. Wan, MSCenters for Disease Control and Prevention; Atlanta, GA 30333 (Dworkin, Wan)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-2-200101160-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:Gulick and colleagues (1) reported that 36% of patients treated with indinavir in a clinical trial had at least one episode of nephrolithiasis during 3 years of follow-up They noted that this incidence was higher than previously reported. To evaluate the risk for nephrolithiasis in a large, diverse cohort of HIV-infected patients, we analyzed data in the Adult and Adolescent Spectrum of HIV Disease Project (ASD) (1998–1999), an observational surveillance study in more than 100 inpatient and outpatient facilities in 11 U.S. cities (2).One hundred eighty-three episodes of nephrolithiasis were diagnosed in 162 of 16 615 ...References1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Meibohm A, Condra JH, et al . 3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine. Ann Intern Med. 2000;133:35-9. LinkGoogle Scholar2. Dworkin MS, Wan PC, Hanson DL, Jones JL. Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis. 1999;180:621-5. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAuthors: Mark S. Dworkin, MD, MPHTM; Pei-Chun T. Wan, MSAffiliations: Centers for Disease Control and Prevention; Atlanta, GA 30333 (Dworkin, Wan) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee Also3-Year Suppression of HIV Viremia with Indinavir, Zidovudine, and Lamivudine Roy M. Gulick , John W. Mellors , Diane Havlir , Joseph J. Eron , Anne Meibohm , Jon H. Condra , Fred T. Valentine , Deborah McMahon , Charles Gonzalez , Leslie Jonas , Emilio A. Emini , Jeffrey A. Chodakewitz , Robin Isaacs , and Douglas D. Richman Metrics Cited byIndinavirANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONSTrends in Nephropathy Among HIV-Infected PatientsShort Communication: Lack of Indinavir-Associated Nephrological Complications in HIV-Infected Adults (Predominantly Women) with High Indinavir Plasma Concentration in Abidjan, Côte d'IvoireIndinavirUrinary pH in HIV-infected adults in Ivory Coast and in FranceAntiviral drugsNews in brief ... 16 January 2001Volume 134, Issue 2Page: 165KeywordsAtrial septal defectClinical trial reportingCohort studiesHIVInpatientsMedical risk factorsObservational studiesOutpatientsRacial and ethnic issuesRelative risk ePublished: 16 January 2001 Issue Published: 16 January 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...